Apatinib-d8 25-N-Oxide Dihydrochloride

Apatinib-d8 25-N-Oxide Dihydrochloride is a deuterated analog of Apatinib, which is a tyrosine kinase inhibitor that specifically targets vascular endothelial growth factor receptor 2 (VEGFR-2). This compound has been used in the treatment of various cancers, including gastric cancer, colorectal cancer, and non-small cell lung cancer. Apatinib-d8 25-N-Oxide Dihydrochloride is a highly purified and stable compound that is supplied as a white to off-white powder. It has a molecular formula of C24H21D8Cl2N4O3 and a molecular weight of 550.42 g/mol. This compound has a purity of 98% or higher, as determined by HPLC and NMR analysis. The usage of Apatinib-d8 25-N-Oxide Dihydrochloride is primarily in research and development of new drugs for cancer treatment. It can be used as a reference standard for the identification and quantification of Apatinib in biological samples. It can also be used for pharmacokinetic and pharmacodynamic studies of Apatinib. Chemically, Apatinib-d8 25-N-Oxide Dihydrochloride is a deuterated derivative of Apatinib. Deuteration provides an effective means of enhancing drug stability, improving bioavailability, and reducing toxicity. This compound can be safely used in in vivo studies and is not expected to cause any adverse effects on the health of laboratory animals. Overall, Apatinib-d8 25-N-Oxide Dihydrochloride is a valuable tool for cancer researchers and drug developers.